Reviews/Targeted Therapy Breast Cancer/CDK4/6 inhibitors plus endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancer
Cdk46 · BC-CDK-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
This corpus asks whether adding a CDK4/6 inhibitor to hormone (endocrine) therapy helps patients with HR-positive, HER2-negative advanced breast cancer live longer and go longer before their cancer worsens. Three large, well-run randomised trials, one for each drug, consistently show patients stayed free of progression for longer when the inhibitor was added to hormone therapy alone [13][14][15]. For living longer overall, the direct proof in this corpus comes only from two ribociclib trials [16][17]; the trials for palbociclib [13] and abemaciclib [15] reported progression results but no overall-survival result here. The panel judged the progression benefit firmly carried for all three drugs and the survival benefit shown at the class level through ribociclib. The main open point is that drug-specific survival proof for palbociclib and abemaciclib is not present in this corpus.
Three independent first-line, double-blind, placebo-controlled phase 3 trials show a concordant, significant progression-free survival benefit for the inhibitor plus endocrine therapy over endocrine therapy alone: palbociclib [13] hazard ratio 0.58 (95% CI 0.46 to 0.72), ribociclib [14] 0.56 (0.43 to 0.72), and abemaciclib [15] 0.54 (0.41 to 0.72). Overall survival benefit versus endocrine therapy alone is demonstrated by two ribociclib trials, [16] hazard ratio 0.71 (0.54 to 0.95) and [17] 0.72 (0.57 to 0.92). The progression benefit is reinforced in later-line and subgroup settings by the postMONARCH trial [3] (hazard ratio 0.73) and the PALOMA pooled analysis [4]. No overall-survival result for palbociclib or abemaciclib versus endocrine therapy alone appears in this corpus. The contested point: The corpus proves overall-survival benefit only for ribociclib [16][17]; PALOMA-2 [13] reports no overall-survival result and MONARCH 3 [15] reports only progression-free survival, so the survival limb for palbociclib and abemaciclib rests on class-level inference rather than direct evidence here. A secondary point is that the abundant evidence sits on the progression endpoint, a surrogate, while the hard survival endpoint is carried by fewer trials and one drug.
All 24 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Targeted Therapy Breast Cancer, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim asserts OS improvement for all three named drugs, but corpus OS evidence is ribociclib-only ([16],[17]). PALOMA-2 [13] reports no OS result and MONARCH 3 [15] reports only PFS, so a significant OS benefit for palbociclib and abemaciclib is not demonstrated in this corpus.
The abundant evidence supports the PFS limb, a surrogate endpoint; the hard OS endpoint is carried by fewer trials (two) and one drug, so the two-endpoint claim leans on the softer measure for breadth.
Where it remains uncertain. Overall-survival evidence in this corpus is ribociclib-specific; [13] reports no OS result and [15] reports only PFS, so the survival claim for palbociclib and abemaciclib is not directly demonstrated here.
Aleatory
Benefit is not uniform across patients: [4] shows no significant PFS difference in first-line HER2-0 patients (HR 0.79, p = 0.34), and [8] reports BMI-linked variation in PFS.
The load-bearing papers from a corpus of 24, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
First-line RCT establishing significant PFS benefit for palbociclib+ET vs ET alone.
“The median progression-free survival was 24.8 months (95% confidence interval [CI], 22.1 to not estimable) in the palbociclib-letrozole group, as compared with 14.5 months (95% CI, 12.9 to 17.1) in the placebo-letrozole group (hazard ratio for disease progression or death, 0.58; 95% CI, 0.46 to 0.72; P<0.001).”
Panel auditInternal validity: high · scope of inference: First-line PFS benefit of palbociclib+letrozole versus letrozole in ER+/HER2- advanced breast cancer.Key limitations: PFS reported, OS not in abstract · postmenopausal first-line only
First-line RCT establishing significant PFS benefit for ribociclib+ET vs ET alone.
“The duration of progression-free survival was significantly longer in the ribociclib group than in the placebo group (hazard ratio, 0.56; 95% CI, 0.43 to 0.72; P=3.29×10^-6 for superiority).”
Panel auditInternal validity: high · scope of inference: First-line PFS benefit of ribociclib+letrozole versus letrozole in HR+/HER2- advanced breast cancer.Key limitations: PFS reported, OS not in abstract · postmenopausal first-line only
First-line RCT establishing significant PFS benefit for abemaciclib+ET vs ET alone.
“Median progression-free survival was significantly prolonged in the abemaciclib arm (hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P = .000021; median: not reached in the abemaciclib arm, 14.7 months in the placebo arm).”
Panel auditInternal validity: high · scope of inference: First-line PFS benefit of abemaciclib+AI versus AI in HR+/HER2- advanced breast cancer.Key limitations: PFS reported, OS not in abstract · postmenopausal first-line only
Phase 3 RCT extending PFS benefit of CDK4/6i+ET over placebo+ET to the post-progression setting (HR 0.73).
“Abemaciclib + fulvestrant significantly improved PFS after disease progression on previous CDK4/6i + ET in patients with HR+, HER2- ABC, offering an additional targeted therapy option for these patients.”
Panel auditInternal validity: high · scope of inference: PFS benefit of abemaciclib+fulvestrant versus fulvestrant after prior CDK4/6i progression in HR+/HER2- ABC.Key limitations: post-progression population not first-line · PFS only, no OS · nominal P values
4 of 24 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus firmly carries the PFS claim across all three drugs and the OS claim at class level via ribociclib, placing confidence inside the Established band though not at its top given the drug-specific OS gap.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Palbociclib overall-survival result versus endocrine therapy alone. The claim names palbociclib for the OS endpoint, yet [13] reports only PFS; no OS figure for palbociclib appears in this corpus. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A mature overall-survival readout from a first-line palbociclib-plus-endocrine-therapy versus placebo-plus-endocrine-therapy RCT.
Open question: Do palbociclib and abemaciclib each significantly improve overall survival versus endocrine therapy alone in first-line HR-positive, HER2-negative advanced breast cancer? Why it is still open: The corpus carries OS proof only for ribociclib [16][17]; [13] reports no OS result and [15] reports only PFS.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 23 Oct 2026 · protocol v0.19